PL EN
REVIEW PAPER
Toxoplasma gondii as a potential modifier of schizophrenia risk: Epidemiological evidence, mechanisms and candidate biomarkers
 
More details
Hide details
1
Faculty of Medicine, Medical University of Silesia
 
 
Submission date: 2026-03-31
 
 
Final revision date: 2026-10-14
 
 
Acceptance date: 2026-11-13
 
 
Online publication date: 2026-11-19
 
 
Corresponding author
Nikodem Świderski   

Faculty of Medicine, Medical University of Silesia
 
 
 
KEYWORDS
TOPICS
ABSTRACT
Schizophrenia is a multifactorial psychiatric disorder in which environmental exposures, including infections, interact with genetic vulnerability. Among neurotropic pathogens, the intracellular protozoan parasite Toxoplasma gondii has attracted particular attention because of its ability to establish chronic cysts in the brain and to manipulate host behavior in animals. Epidemiological studies consistently report higher seroprevalence of T. gondii among patients with schizophrenia compared with controls, especially in early stages of psychosis. Experimental, animal, and bioinformatic studies have proposed several mechanisms through which Toxoplasma gondii exposure or chronic infection could plausibly be related to neurobiological processes relevant to schizophrenia. This narrative review synthesises current evidence on the molecular pathways linking T. gondii infection to schizophrenia, with a particular focus on mechanisms amenable to therapeutic modulation and on candidate biomarkers proposed to stratify infected individuals, none of which has yet been validated as a predictor of schizophrenia risk. PubMed and related databases were searched for clinical, experimental, and in silico studies examining T. gondii, schizophrenia, molecular or immunological mechanisms, and biomarkers up to February 2026. The literature most consistently supports an epidemiological association between T. gondii seropositivity and schizophrenia. Proposed mechanistic links – including kynurenine-pathway alterations, glial activation, molecular mimicry, neurotransmitter dysregulation, and T-cell changes – are supported to varying degrees by animal, in vitro, biomarker, and computational studies, but remain insufficiently validated as causal pathways in humans. Exploratory candidate biomarkers, none yet validated in humans as predictors, include refined serological measures (e.g. antibodies to the cyst matrix antigen MAG1, studied mainly in mice, and serotype-specific responses), autoantibodies to NMDAR, kynurenine pathway metabolites, neurobiological and immune serum markers (KLK6, UCHL1, neurogranin, IL‑10, IL‑8, MIP‑1β), markers of neuronal injury and innate immune activation (neuron‑specific enolase, IL‑18), and hair glucocorticoid levels.
eISSN:2545-1898
Journals System - logo
Scroll to top